ORCL
68
-3
SPG
60
-3
CRM
69
-6
R
75
-2
HP
37
-8
RIG
50
6
FCX
56
2
GD
46
-13
DVN
21
-8
LNC
43
-2
RSG
70
-7
MDT
57
-2
AAL
59
2
NDAQ
59
-4
TGNA
56
-3
HPE
48
-22
LRCX
48
2
ORLY
66
-3
SE
57
-3
DE
39
3
ORCL
68
-3
SPG
60
-3
CRM
69
-6
R
75
-2
HP
37
-8
RIG
50
6
FCX
56
2
GD
46
-13
DVN
21
-8
LNC
43
-2
RSG
70
-7
MDT
57
-2
AAL
59
2
NDAQ
59
-4
TGNA
56
-3
HPE
48
-22
LRCX
48
2
ORLY
66
-3
SE
57
-3
DE
39
3
Financhill
Back

Editas Medicine 10K Form

Sell
43

EDIT
Editas Medicine

Last Price:
2.67
Seasonality Move:
16.26%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive EDIT News And Ratings

See the #1 stock for the next 7 days that we like better than EDIT

EDIT Financial Statistics

Sales & Book Value

Annual Sales: $78.12M
Cash Flow: $-55.51M
Price / Cash Flow: 0
Annual Sales: $2.13
Price / Book: 1.3

Profitability

EPS (TTM): -2.56000
Net Income (TTM): $-210.57M
Gross Margin: --
Return on Equity: -74.59%
Return on Assets: -48.82%

Editas Medicine Earnings Forecast

Key Editas Medicine Financial Ratios

  • The Research & Development expenses have been 227.40% of Revenue.
  • The Interest Expense is 5.47% of Operating Income.
  • The Net Earning history of EDIT is -196.13% of Total Revenues.
  • Per Share Earnings over the last 10 years have been positive in 4 years.

Editas Medicine Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: EDIT
CUSIP: 28106W
Website: editasmedicine.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 3.75
Quick Ratio: 3.67

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

EDIT Technical Analysis vs Fundamental Analysis

Sell
43
Editas Medicine (EDIT) is a Sell

Is Editas Medicine a Buy or a Sell?

  • Editas Medicine stock is rated a Sell
    The current Editas Medicine [EDIT] share price is $2.77. The Score for EDIT is 43, which is 14% below its historic median score of 50, and infers higher risk than normal.